omaveloxolone Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Omaveloxolone is a second generation member of the synthetic oleanane triterpenoid compounds and currently in clinical development by Reata Pharmaceuticals. Preclinical studies have demonstrated that omaveloxolone possesses antioxidative and anti-inflammatory activities and the ability to improve mitochondrial bioenergetics. Omaveloxolone is currently under clinical investigation for a variety of indications, including Friedreich’s ataxia, mitochondrial myopathies, immunooncology, and prevention of corneal endothelial cell loss following cataract surgery.   Wikipedia

Chemistry

  • SMILES: CC(C)(C)C(=O)C[C@]12CCC(C)(C)C[C@H]1[C@H]3C(=O)C=C4[C@@](C)(CC[C@H]5C(C)(C)C(=O)C(=C[C@]45C)C#N)[C@]3(C)CC2
  • InChIKey: JVOADWNONSFZQK-ONLUTREGSA-N
  • Mol. Mass: 545.81
  • ALogP: 8.21
  • ChEMBL Molecule:
    omaveloxolone  
More Chemistry

Pharmacology

Alternative names

n-(11-cyano-2,2,6a,6b,9,9,12a-heptmethyl-10,14-dioxo-1,3,4,5,6a,6b,7,8,8a,9,10,12a,14,14a,14b-hexadecahydro-2h-picen-4a-yl)-2-2-difluoropropionamide | omaveloxolone | rta 408 | rta-408

Organizations (4)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (11)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (11)


 

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Corneal Endothelial Cell Loss (Phase 2)

Friedreich Ataxia (Phase 2)

General Surgery (Phase 2)

Healthy Volunteers (Phase 1)

Inflammation (Phase 2)

Liver Diseases (Phase 1)

Melanoma (Phase 2)

Mitochondrial Myopathies (Phase 2)

Pain (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 13
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue